Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
MR Differential Diagnosis of Normal-Pressure Hydrocephalus and Alzheimer Disease:Significance of Perihippocampal Fissures
AJNR 19:813-819, Holodny,A.I.,et al, 1998
Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimers Disease Neuroimaging Initiative
AJNR 36:653-660, Chow, N.,et al, 2015
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD
Neurol 75:143-151, Vemuri,P., et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Association of Plasma Leptin Levels With Incident Alzheimer Disease and MRI Measures of Brain Aging
JAMA 302:2565-2572, 2593, Lieb,W.,et al, 2009
Fully-Automated Quantification of Regional Brain Volumes for Improved Detection of Focal Atrophy in Alzheimers Disease
AJNR 30:578-580, Brewer, J.B.,et al, 2009
Low Body Weight in Alzheimer's Disease is Associated with Mesial Temporal Cortex Atrophy
Neurol 46:1585-1591, Grundman,M.,et al, 1996
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Imaging Cerebral Atrophy:Normal Ageing to Alzheimer's Disease
Lancet 363:392-394, Fox,N.C.&Schott,J.M., 2004
Neuro-Ophthalmic Findings in the Visual Variant of Alzheimers Disease
Ophthalmology 111:376-381, Lee,A.G. &Martin,C.O., 2004
Magnetic Resonance Spectroscopy in AD
Neurol 56:592-598, Valenzuela,M.J.,et al, 2001
Altered Brain Activation in Cognitively Intact Individuals at High Risk for Alzheimer's Disease
Neurol 53:1391-1396, Smith,C.D.,et al, 1999
Functional Magnetic Resonance Imaging in Neuropsychiatry
BMJ 319:1551-1554, Longworth,C.,et al, 1999
Noninvasive Perfusion MRI in Alzheimer's Disease:A Preliminary Report
Neurol 47:1339-1342, Sandson,T.A.,et al, 1996
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Amygdala Atrophy in Alzheimer's Disease, An In Vivo MRI Study
Arch Neurol 50:941-945, Cuenod,C.A.,et al, 1993
End-State Alzheimer's Disease:Glasgow Coma Scale and the Neurologic Examination
Arch Neurol 50:1309-1315, Benesch,C.G.,et al, 1993
Assessing the Severity of Dementia:Patient and Caregiver
Arch Neurol 48:274-277, Tuenisse,S.,et al, 1991
Demonstration of CSF Gamma-globulin Banding in Presenile Dementia
Neurol 30:882-884, Williams,A.,et al, 1980
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Revised Criteria for Diagnosis and Staging of Alzheimers Disease: Alzheimers Association Workgroup
Alzheimers Dement 20:5143-5169, Jack,Jr.,C.R.,et al, 2024
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Visuospatial deficits in posterior cortical atrophy: structural and functional correlates
JNNP 83:860-863,855, Andrade, K.,et al, 2012
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Neurodegenerative causes of death among retired National Football League Players
Neurol 79:1970-1974, Lehman, E.,et al, 2012
CSF biomarkers in posterior cortical atrophy
Neurol 76:1782-1788, Seguin, J.et al, 2011
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Rapidly Progressive Alzheimer Disease
Arch Neurol 68:1124-1130, Schmidt, C.,et al, 2011
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
In Vivo Mapping of Amyloid Toxicity in Alzheimer Disease
Neurol 72:1504-1511, Frisoni,B.G.,et al, 2009
Age, Neuropathology, and Dementia
NEJM 360:2302-2309, Savva,G.M.,et al, 2009
CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment
JAMA 302:385-393,436,452, Mattsson,N.,et al, 2009
Positron Emission Tomography in Diagnosis of Visual Variant Alzheimer Disease
J Neuro-Ophthalmol 29:149-150, Finelli,P.F., 2009
Conversion of Amyloid Positive and Negative MCI to AD over 3 Years: An 11C-PIB PET Study
Neurol 73:754-760, 744, Okello,A.,et al, 2009
Association of Parental Dementia With Cognitive and Brain MRI Measures in Middle-Aged Adults
Neurol 73:2071-2078, 2054, Debette,S.,et al, 2009